Investigating the role of inorganic pyrophosphate in children with chronic kidney disease
Official title: Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA
Run by Centre Hospitalier Universitaire de Nice · NCT06300788 · Data updated 2026-11-12
This study is testing how a substance called inorganic pyrophosphate affects blood vessel health in children with chronic kidney disease to see if it can help prevent related problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Years to 18 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes-Maritimes) |
| Status | Recruiting |
| Started | May 27, 2024 |
| Main results expected | November 27, 2027 |
| Study ends | November 27, 2027 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT06300788 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are minors under 18 years old with chronic kidney disease, including those on dialysis or who have received a kidney transplant.
✕Probably not a fit
Patients with progressive cancer or kidney disease, or those on treatments that may alter pyrophosphate levels, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the role of inorganic pyrophosphate and other anti-calcifying molecules in the development of vascular disease among children suffering from chronic kidney disease (CKD). It will involve measuring serum levels of these molecules in children with CKD and comparing them to healthy controls matched by age and sex. Additionally, the study will assess vascular function through clinical evaluations and ultrasound techniques to better understand the pathophysiology of vascular calcification. The ultimate goal is to identify potential therapeutic approaches to limit vasculopathy onset in these patients.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies to prevent vascular complications in children with chronic kidney disease.
How similar studies have gone: While the specific approach of this study may be novel, previous studies have indicated the importance of pyrophosphate in vascular health, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All groups : * Minor patients (\<18 years) * Patients of both sexes * Informed patients and parents who have signed the informed consent form * Patients affiliated to social security Control group : \- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up CKD groups : * Patients on dialysis for more than 3 months, regardless of technique * Kidney transplant patients * Patients with CKD, whatever the cause Exclusion Criteria: * Progressive cancer or kidney disease * Treatments that may modify PPi concentration (e.g. bisphosphonates)
Where it's running
-
CHU Nice - Hôpital de l'Archet 2
Nice, Alpes-Maritimes, France Recruiting
Study contacts
- Study coordinator: Julie BERNARDOR
- Email: bernardor.j@chu-nice.fr
- Phone: 04.92.03.63.65
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.